Tides Express | Xiyan Bio's Small Nucleic Acid Drug LDR2402 Enrolls First Subject in Phase I Clinical Trial

November 202418th，Leaderna Therapeutics Ltd. (hereinafter referred to as "Leaderna") announced that the first subject has been enrolled in a Phase I clinical trial in China for its self-developed novel small nucleic acid drug LDR2402 injection, which targets angiotensinogen (AGT), marking the beginning of a new generation of treatments for primary hypertension.This is the second small nucleic acid variety clinical study conducted by Leaderna.

On August 29, the Investigational New Drug (IND) application for LDR2402 injection was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. Recently, LDR2402 injection has been approved by the NMPA to conduct clinical trials.

About LDR2402 Injection

LDR2402 Injection is a novel small nucleic acid drug developed based on RNA interference (RNAi) technology. In preclinical experiments, it significantly reduces the level of angiotensinogen (AGT), with effects lasting over six months after a single injection. AGT is the origin of the renin-angiotensin-aldosterone system (RAAS) mechanism. LDR2402 selectively enters the liver, silencing AGT expression at the source to achieve blood pressure reduction. In clinical treatment, LDR2402 may improve patient compliance by extending the dosing interval (once per quarter or semi-annually), while providing steady blood pressure reduction within 24 hours, reducing blood pressure variability (BPV), and offering greater cardiovascular benefits to hypertensive patients.